Giant cell arteritis: Clinical aspects

Inflammatory Diseases of Blood Vessels

Volumn , Issue , 2016, Pages 425-441

  Hunder, Gene G ^a   Valente, Robert M ^b  

^a MAYO CLINIC   (United States)

^b Arthritis Center of Nebraska   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85051305833     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (86)

1. Gilmour JR, Giant-cell arteritis, J Pathol Bacteriol 1941; 53:263-277.
2. Horton BT, Magath TB, Brown GE, An undescribed form of arteritis of the temporal vessels, Proc Staff Meet Mayo Clin 1932; 7:700-701.
3. Kilboume ED, Wolff HH, Cranial arteritis: A critical evaluation of the syndrome of "temporal arteritis" with report of a case, Ann Intern Med 1946; 24: 1-10.
4. McMillan Gc, Diffuse granulomatous aortitis with giant cells: Associated with partial rupture and dissection of the aorta, Arch Pathol 1950; 49:63-69.
5. Salvarani C, Gabriel SE, O'Fallon WM, et al, The incidence of giant cell arteritis in Olmsted County, Minnesota: Apparent fluctuations in cyclic pattern, Ann Intern Med 1995; 123:192-194.
6. Wilkinson MS, Russell RWR, Arteries of the head and neck in giant cell arteritis: A pathological study to show the pattern of arterial involvement, Arch NeurolI972; 27:378-391.
7. Klein RG, Hunder GG, Stanson AW, et al, Large artery involvement in giant cell (temporal) arteritis, Ann Intern Med 1975; 83:806-812.
8. Baldursson 0, Steinsson K, Bjornsson J, et al, Giant cell arteritis in Iceland, An epidemiologic and histologic analysis, Arthritis Rheum 1994; 37: 1007-1012.
9. Nordborg E, Bengtsson B-A, Epidemiology of biopsy-proven giant cell arteritis (GCA), J Intern Med 1990; 227:233-236.
10. Gran IT, Myklebust G, The incidence of polymyalgia rheumatica and temporal arteritis in the county of Aust Agder, South Norway: A prospective study 1987-94, J Rheumatol 1997; 24(9): 1739-1743.
11. Boesen P, Sorensen SF, Giant cell arteritis, temporal arteritis and polymyalgia rheumatica in a Danish county: A prospective investigation, 1982-1985, Arthritis Rheum 1987; 30:294-299.
12. Barrier J, Pion P, Massari R, et al, Epidemiologic approach to Horton's disease in Department of LoireAtlantique: 110 cases in 10 years (1970-1979), Rev Med Interne 1983; 3:13-20.
13. Espy MJ, Gabriel SE, Bjornsson J, et al, The role ofparvovirus B19 in the pathogenesis of giant cell arteritis: A preliminary evaluation, Arthritis Rheum 1999; 42:1255-1258.
14. Elling P, Olsson AT, Elling H, Synchronous variations of the incidence of temporal arteritis and polymyalgia rheumatica in different regions of Denmark: Association with epidemics of Mycoplasma pneumoniae infection, J Rheumatol 1996; 23(1):112-119.
15. Ostberg G, Temporal arteritis in a large necropsy series, Ann Rheum Dis 1971; 30:224-235.
16. Salvarani C, Gabriel SE, O'Fallon WM, et al, Epidemiology of polymyalgia rheumatica in Olmsted County, Minnesota, 1970-1991, Arthritis Rheum 1995; 38:369-373.
17. Calamia KT, Hunder GG, Clinical manifestations of giant cell arteritis, Clin Rheum Dis 1980; 6:389403.
18. Calamia KT, Hunder GG, Giant cell arteritis (temporal arteritis) presenting as fever of undetermined origin, Arthritis Rheum 1981; 24:1414-1418.
19. Casselli RJ, Hunder GG, Whisnant JP, Neurologic disease in biopsy-proven giant cell (temporal) arteritis, Neurology 1988; 38:352-359.
20. Aiello PD, Trautmann JC, McPhee TJ, et al, Visual prognosis in giant cell arteritis, Ophthalmology 1993; 100:550-555.
21. Hayreh SS, Podhajsky PA, Zimmerman B, Ocular manifestations of giant cell arteritis, Am J Ophthalmol 1998; 125(4):509-520.
22. Lee CC, Su WW, Hunder GG, Dysarthria associated with giant cell arteritis, J Rheumatol 1999; 26(4): 931-932.
23. Larson TS, Hall S, Hepper NGG, et al, Respiratory tract symptoms as a clue to giant cell arteritis, Ann Intern Med 1984; 101:594-597.
24. Rudd JC, Fineman MS, Sergott RC, Ischemic scalp necrosis preceding loss of visual acuity in giant cell arteritis, Arch Ophthalmol 1998; 116(12):1690-1691.
25. Caselli RJ, Hunder GG, Giant cell (temporal) arteritis, Neurol Clin 1997; 15(4):893-902.
26. Caselli RJ, Giant cell (temporal) arteritis: A treatable cause of multi-infarct dementia, Neurology 1990; 40:753-755.
27. Hamrin B, Polymyalgia arteritica, Acta Med Scand 1972; (suppl) 533.
28. Lie IT, Aortic and extracranial large vessel giant cell arteritis: A review of 72 cases with histopathologic documentation, Semin Arthritis Rheum 1995; 24:422-431.
29. Stanson AW, Klein RG, Hunder GG, Extracranial angiographic findings in giant cell (temporal) arteritis, Am J Roentgenol 1976; 127:957-963.
30. Brack A, Martinez-Taboada V, Stanson A, Goronzy JJ, Weyand CM, Disease pattern in cranial and large-vessel giant cell arteritis, Arthritis Rheum 1999; 42(2):311-3 17.
31. Freddo T, Price M, Kase C, Goldstein MP, Myocardial infarction and coronary artery involvement in giant cell arteritis, Optom Vis Sci 1999; 76(1): l4-18.
32. Bahlas S, Ramos-Remus C, Davis P, Clinical outcome of 149 patients with polymyalgia rheumatica and giant cell arteritis, J Rheumatol 1998:25(1):99-104.
33. Weyand CM, Fulbright JW, Evans IM, Hunder GG, Goronzy JJ, Corticosteroid requirements in polymyalgia rheumatica, Arch Intern Med 1999; 159(6):577-584.
34. Salvarani C, Cantini F, Olivieri I, Barozzi L, Macchioni L, Niccoli L, Padula A, De Matteis M, Pavlica P, Proximal bursitis in active polymyalgia rheumatica, Ann Intern Med 1997; 127(l):27-31.
35. Salvarani C, Cantini F, Macchioni P, Olivieri I, Niccoli L, Padula A, Boiardi L, Distal musculoskeletal manifestations in polymyalgia rheumatica: A prospective follow-up study, Arthritis Rheum 1998; 41(7): 1221-1226.
36. Salvarani C, Gabriel S, Hunder G, Distal extremity swelling with pitting edema in polymyalgia rheumatica, Arthritis Rheum 1996; 39:73-80.
37. Salvarani C, Hunder GG, Musculoskeletal manifestations in a population-based cohort of patients with giant cell arteritis, Arthritis Rheum 1999; 42:1259-1266.
38. Hunder GG, Giant cell arteritis and polymyalgia rheumatica, Med Clin North Am 1997; 81(l):195219.
39. Weyand CM, Hicok KC, Hunder GG, et al, Tissue cytokine patterns in patients with polymyalgia rheumatica and giant cell arteritis, Ann Intern Med 1994; 121 :484-491.
40. Evans 1M, Bowles CA, Bjornsson 1, et a1, Thoracic aortic aneurysm and rupture in giant cell arteritis, A descriptive study of 41 cases, Arthritis Rheum 1994; 37: 1539-1547.
41. Evans 1M, O'Fallon WM, Hunder GG, Increased incidence of aortic aneurysm and dissection in giant cell (temporal) arteritis: A population-based study, Ann Intern Med 1995; 122:502-507.
42. Lie IT, Aortic and extracranial large vessel giant cell arteritis: A review of 72 cases with histopathologic documentation, SeminArthritis Rheum 1995; 24(6):422-431.
43. Malrnvall B-E, Bengtsson B-A, Kaijser B, et a1, Serum levels of immunoglobulin and complement in giant cell arteritis, lAMA 1976; 236:1876-1878.
44. Kyle V, Laboratory investigations including liver in polymyalgia rheumatica/giant cell arteritis, Baillieres Clin Rheumatol 1991; 5(3):475-484.
45. Pountain GD, Calvin 1, Hazleman BL, Alpha I-antichymotrypsin, C-reactive protein and erythrocyte sedimentation rate in polymyalgia rheumatica and giant cell arteritis, Br 1 Rheumatol 1994; 33(6): 550-554.
46. Salvarani C, Macchioni P, Boiardi L, Rossi F, Casadei Maldini M, Mancini R, Beltrandi E, Spacca C, Lodi L, Portioli I, Soluble interleukin 2 receptors in polymyalgia rheumatica/giant cell arteritis, Clinical and laboratory correlations, 1 Rheumatol 1992; 19(7): 1100-1106.
47. Hachulla E, Salie R, Parra Hl, Hatron PY, Gosset D, Fruchart lC, Devulder B, Serum amyloid A concentrations in giant-cell arteritis and polymyalgia rheumatica: A useful test in the management of the disease, Clin Exp Rheumatol 1991; 9(2):157-163.
48. Zweegman S, Makkink B, Stehouwer CD, Giant-cell arteritis with normal erythrocyte sedimentation rate: Case report and review ofthe literature, Netherlands 1 Med 1993; 42(3-4):128-131.
49. Neish PR, Sergent lS, Giant cell arteritis, A case with unusual neurologic manifestations and a normal sedimentation rate, Arch Intern Med 1991; 151(2):378-380.
50. Roche NE, Fulbright JW, Wagner AD, et al, Correlation of interleukin-6 production and disease activity in polymyalgia rheumatica and giant cell arteritis, Arthritis Rheum 1993; 36:1286-1294.
51. Weyand CM, Fulbright lW, Evans IM, et a1, Corticosteroid requirements in polymyalgia rheumatism, Arch Intern Med 1999; 159:577-584.
52. Weyand CM, Fulbright JW, Hunder GG, Goronzy JJ, Corticosteroid requirements in giant cell arteritis, Submitted for publication.
53. IIan Y, Ben-Chetrit E, Liver involvement in giant cell arteritis, Clin Rheumatol 1993; 12(2):219-222.
54. Kyle V, Wraight EP, Hazleman BL, Liver scan abnormalities in polymyalgia rheumatica/giant cell arteritis, Clin Rheumatol 1991; 10(3):294-297.
55. Rousselet MC, Kettani S, Rohmer V, Saint-Andre IP, A case of temporal arteritis with intrahepatic arterial involvement, Pathol Res Pract 1989; 185(3):329-331.
56. Sherard RK, Coleridge ST, Giant-cell arteritis, 1 Emerg Med 1986; 4(4):293-299.
57. Brooke MH, Kaplan H, Muscle pathology in rheumatoid arthritis, polymyalgia rheumatica, and polymyositis: A histochemical study, Arch PathoI1972; 94:101-118.
58. Persellin ST, Daniels TM, Rings LJ, et a1, Factor VIII-von Willebrand factor in giant cell arteritis and polymyalgia rheumatica, Mayo Clin Proc 1985;60:457-462.
59. Olsson A, Elling P, Elling H, Serologic and immunohistochemical determination of von Willebrand factor antigen in serum and biopsy specimens from patients with arteritis temporalis and polymyalgia rheumatica, Clin Exp Rheumatol 1990; 8:55-58.
60. Meyer D, Nicaise P, Moreau S, de Bandt M, Palazzo E, Hayem G, Chazerain P, Labarre C, Kahn ME Antibodies to cardiolipin and beta 2 glycoprotein I in patients with polymyalgia rheumatica and giant cell arteritis, Revue du Rhumatisme, English Edition 1996; 63(4):241-247.
61. Manna R, Latteri M, Cristiano G, Todaro L, Scuderi F, Gasbarrini G, Anticardiolipin antibodies in giant cell arteritis and polymyalgia rheumatica: A study of 40 cases, Br J Rheumatol 1998; 37(2):208210.
62. Nordborg E, Nordborg C, The inflammatory reaction in giant cell arteritis: An immunohistochemical investigation, Clin Exp Rheumatol 1998; 16(2):165-168.
63. Carson CW, Beall LD, Hunder GG, et al, Serum ELAM-l is increased in vasculitis, scleroderma, and systemic lupus erythematosus, J Rheumatol 1992; 20:809-814.
64. Macchioni P, Boiardi L, Meliconi R, Salvarani C, Grazia Uguccioni M, Rossi F, Pulsatelli L, Facchini A, Elevated soluble intercellular adhesion molecule 1 in the serum of patients with polymyalgia rheumatica: Influence of steroid treatment, J Rheumatol 1994; 21(10): 1860-1864.
65. Coll-Vinent B, Viiardell C, Font C, Oristrell J, Hernandez-Rodriguez J, Yague J, Urbano-Marquez A, Grau JM, Cid Me, Circulating soluble adhesion molecules in patients with giant cell arteritis, Correlation between soluble intercellular adhesion molecule-l (sICAM-l) concentrations and disease activity, Ann Rheum Dis 1999; 58(3): 189-192.
66. Klein RG, Campbell RJ, Hunder GG, Carney JA, Skip lesion in temporal arteritis, Mayo Clin Proc 1976; 51(8):504-510.
67. Achkar AA, Lie JT, Hunder GG, et al, How does previous corticosteroid treatment affect the biopsy findings in giant cell (temporal) arteritis? Ann Intern Med 1994; 120:987-992.
68. Evans JM, Batts KP, Hunder GG: Persistent giant cell arteritis despite corticosteroid treatment, Mayo Clin Proc 1994; 69:1060-1061.
69. Gabriel SE, O'Fallon WM, Achkar AA, et al, The use of clinical characteristics to predict the results of temporal artery biopsy among patients with suspected giant cell arteritis, J Rheumatol 1995; 22: 93-96.
70. Lie JT, Illustrated histopathologic classification criteria for selected vasculitis syndromes, American College of Rheumatology Subcommittee on Classification of Vasculitis, Arthritis Rheum 1990; 33(8): 1074-1087.
71. Puechal X, Chauveau M, Menkes CJ, Temporal doppler-flow studies for suspected giant-cell arteritis, Lancet 1995; 345:1437-1438.
72. Barrier J, Potel G, Renaut-Hovasse H, et al, The use of Doppler flow studies in the diagnosis of giant cell arteries: Selection of temporal artery biopsy site is facilitated, JAMA 1982; 248:2158-2159.
73. Schmidt WA, Kraft HE, Vorpahl K, Volker L, Gromnica-Ihle EJ, Color duplex ultrasonography in the diagnosis of temporal arteritis, N Engl J Med 1997; 337: 1336-1342.
74. Hall S, Persellin S, Lie JT, O'Brien PC, et al, The therapeutic impact of temporal artery biopsy, Lancet 1983; 2:1217-1220.
75. Hall S, Hunder GG, Is temporal artery biopsy prudent? Mayo Clin Proc 1984; 59(11):793-796.
76. Lie JT: When is arteritis of the temporal arteries not temporal arteritis? J Rheum 1994; 21:186-189.
77. Lie JT, Temporal artery biopsy diagnosis of giant cell arteritis: Lessons from 1109 biopsies, Anat Patho11996; 1:69-97.
78. Gertz MA, Kyle RA, Griffing WL, et al, Jaw claudication in primary systemic amyloidosis, Medicine 1986; 65:173-179.
79. Hunder GG, Bloch DA, Michel BA, et al, The American College of Rheumatology 1990 Criteria for the Classification of Giant Cell Arteritis, Arthritis Rheum 1990; 33: 1122-1128.
80. Hunder GG, Weyand CM, Sonography in giant-cell arteritis, N Engl J Med 1997; 337:1385-1386.
81. Hunder GG, Sheps SG, Allen GL, et al, Daily and alternate-day corticosteroid regimens in treatment of giant cell arteritis: Comparison in a prospective study, Ann Intern Med 1975; 82:613-618.
82. van der Veen MJ, Dinant HJ, van Booma-Frankfort C, van Albada-Kuipers GA, Bijlsma JW, Can methotrexate be used as a steroid sparing agent in the treatment of polymyalgia rheumatica and giant cell arteritis? Ann Rheum Dis 1996; 55(4):218-223.
83. Hernandez-Garcia C, Soriano C, Morado C, Ramos P, Fernandez-Gutierrez B, Herrero M, Banares A, Jover JA, Methotrexate treatment in the management of giant cell arteritis, Scand J Rheumatol 1994; 23(6):295-298.
84. Feinberg HL, Sherman JD, Schrepferman CG, Dietzen CJ, Feinberg GD, The use of methotrexate in polymyalgia rheumatica, J Rheumatol 1996; 23(9):1550-1552.
85. De Silva M, Hazleman BL, Azathioprine in giant cell arteritis/polymyalgia rheumatica: A double-blind study, Ann Rheum Dis 1986; 45(2): 136-138.
86. Proven A, Gabriel S, Hunder G, Treatment outcome in a cohort of patients with giant cell arteritis, In preparation.